Shares of Bioanalytical Systems Inc. (BASI), which closed at a new 52-week high of $5.33 yesterday, are up over 300 percent year-to-date.
The IPO activity in the U.S. healthcare sector has had a strong showing so far in the last quarter of the year, with 12 listings in the month of October alone.
Shares of Mirum Pharmaceuticals Inc. (MIRM) are down nearly 46% since their market debut on July 18, 2019.
The U.S. healthcare sector has witnessed 11 IPOs so far this month. Let's take a look at what's in store for the week ahead.
Phathom Pharmaceuticals Inc., a late clinical-stage biopharmaceutical company developing treatments for gastrointestinal diseases, is all set to list its common stock on the Nasdaq Global Market under the symbol "PHAT" on October 25, 2019.
Shares of Zynex Inc. (ZYXI) which touched an all-time intraday high of $13.10 on October 7, 2019, a gain of a whopping 345 percent year-to-date, have given back some of the gains and trade around $10.
The following companies belonging to the healthcare sector are slated to debut on the U.S. public market in the week ahead.
1. Happiness Biotech Group Ltd
China-based Happiness Biotech Group Limited is a nutraceutical and dietary supplements producer, developing a variety of products made from...
Shares of Carl Zeiss Meditec AG (AFX.F) are up 52 percent year-to-date on the Frankfurt Stock Exchange while the German benchmark index, the DAX, has gained 20 percent for the same period.
Melinta Therapeutics Inc. (MLNT), which has gained 59 percent over the last two months, awaits a regulatory catalyst next week.
Shares of Biofrontera AG (B8F.F) (BFRA) are currently down 5.61% on the Frankfurt Stock Exchange, trading at EUR 5.05.
Marseille, France-based Innate Pharma S.A., is a biotechnology company developing therapeutic antibodies for the treatment of oncology indications with unmet medical need.
Shares of Germany-based 4SC AG (VSE), which trade on the Frankfurt Stock Exchange, have gained 7 percent over the last seven trading days.
We are just one week into the fourth quarter of the year. The week that just wrapped up saw 3 biotech companies making their public debut, and one company, ADC Therapeutics, withdrawing its IPO filing, citing adverse market conditions.
Shares of Evofem Biosciences Inc. (EVFM) are up 22 percent year-to-date while the iShares Nasdaq Biotechnology ETF (IBB), a bellwether of investor sentiment, has gained only 2.5 percent for the same period.
The IPO activity in the U.S. pharma/biotech sector has had a strong showing so far this year, with 46 listings in the 9-month period of the year and 12 listings in the third quarter.